Quarterly results

We announce our results on a quarterly basis.

 

This section contains details of our results announcements, to view and download, along with links to related webcasts and presentations. Results from previous years are archived by date, and can be accessed via the filter below.

 

Refine by year: You can select a specific year to look at all four quarters of results.








2014 Second Quarter - released on 23 July 2014

Key highlights      

  • Q2 2014 turnover £5.6 billion (-4%) and core EPS 19.1p (-12%) on ex-divestment basis and CER
  • Q2 dividend 19p (+6%)
  • Significant strategic progress made with 3-part Novartis transaction on track for completion in H1 2015
  • Transition of respiratory portfolio underway
  • Further significant pipeline launches, approvals and filings
  • Pipeline opportunity remains substantial with over 40 NMEs in late stage development

2014 First Quarter - released on 30 April 2014

Key highlights

  • Q1 turnover £5.6 billion, -2% (CER) on an ex-divestment* basis
  • Core EPS 21.0p (+2% CER) driven by operating leverage and financial efficiencies
  • First quarter dividend +6% to 19p. Share buy backs of £1-2 billion targeted during 2014
  • Pharmaceutical and Vaccines sales growth in all major regions except US
  • Consumer Healthcare sales flat with Rest of World growth (+6%) offsetting the impact in US and Europe of temporary supply interruptions to certain products

2013 Fourth Quarter - released on 5 February 2014

Key highlights

  • Core EPS of 112.2p (+4% CER) and dividend of 78p (+5%)
  • £5.2 billion of cash returned to shareholders
  • Exceptional year for R&D delivery with approvals for 6 major products and 5 additional regulatory filings completed
  • New product launches strengthen businesses in Respiratory, Vaccines, HIV and Oncology
  • Pipeline opportunity remains substantial with Phase III data for 6 potential new drugs and vaccines and around 10 NME Phase III starts across 2014 and 2015

2013 Third Quarter - released on 23 October 2013

Key highlights

  • Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
  • Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%
  • Consumer Healthcare +4%
  • 4 approvals in 3 markets; Tivicay for HIV and FluLaval Q-IV vaccine for flu; Tafinlar for metastatic melanoma; Relvar Ellipta for asthma
  • Q3 dividend of 19p (+6%)
  • Full year 2013 guidance reaffirmed

2013 Second Quarter - released on 24 July 2013

Key highlights

  • Core EPS growth of 4% on sales growth of 2% (both CER)
  • Pharma & Vaccines +1%; US +5%; EMAP +2%; Europe flat; Japan -5%
  • Consumer Healthcare +2% (+5% excluding divestments)
  • 3 major US approvals: Breo Ellipta for COPD, Tafinlar & Mekinist for metastatic melanoma
  • Q2 dividend of 18p (+6%)
  • Total share repurchases for 2013 to be £1-2bn

 

 

2013 First Quarter - released on 24 April 2013

Key highlights

  • Core EPS of 26.9p and dividend of 18p
  • Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year comparisons
  • Continued R&D pipeline progress
  • Continued delivery of financial efficiencies, strong cash generation and returns to shareholders
  • Further measures to drive strategic focus and improve growth profile
  • 2013 expectations for sales growth (~1%) and core EPS growth (3-4%) unchanged (both at CER)

 

2012 Fourth Quarter - released on 6 February 2013

"In 2012, despite a challenging operating environment, we have maintained core earnings per share on a CER basis, returned over £6.3 billion to shareholders and made outstanding progress to advance potential new medicines across multiple disease areas."


Sir Andrew Witty, CEO

Key highlights

  • Core EPS of 112.7p and returns of £6.3bn to shareholders
  • 2012 dividend of 74p (+6%)
  • Group sales -1%; flat excluding disposals of OTC brands
  • Successful R&D delivery: six new drugs filed since start of 2012

 

2012 Third Quarter - released on 31 October 2012

Key highlights

  • Core EPS of 26.5p
  • Dividend of 18p (+ 6%)
  • Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
  • Continued strong cash generation and returns to shareholders

 

2012 Second Quarter - released on 25 July 2012

"The very significant progress made in our late-stage pipeline provides us with increasing confidence that we have the ability to deliver long-term sustainable sales growth and improving returns to shareholders."

Sir Andrew Witty, CEO

Key highlights

  • Core EPS of 26.4p
  • Dividend of 17p (up 6%)
  • Significant late-stage pipeline delivery

 

2012 First Quarter - released on 25 April 2012

Key highlights

  • Sales growth of +2% CER
  • Further R&D delivery, operational leverage and continued returns to shareholders
  • Core EPS 27.3p (+7%), dividend up 6% to 17p

 

2011 Fourth Quarter - released on 7 February 2012

"Three and a half years ago, we set out to fundamentally change GSK to create a more balanced business capable of addressing the market challenges we face, delivering sustainable financial performance and providing new value to patients and consumers. Our record in 2011 demonstrates that we are succeeding."


Sir Andrew Witty, CEO

Key highlights

  • 2011 underlying sales +4% (reported -3%)
  • EPS before major restructuring* 114.1p
  • Total dividends of 75p

 

2011 Third Quarter - released on 26 October 2011

Key highlights

  • Underlying sales growth of 6% and reported sales growth of 3%
  • EPS before major restructuring 28.5p, dividend 17p (up 6%)
  • Strong contribution from Japan: sales +57%

 

2011 Second Quarter - released on 26 July 2011

"We have had a strong second quarter, with continued underlying sales growth, new product delivery, pipeline visibility and cash generation. This progress is very much in line with our expectations and it is clear that our strategy is delivering."


Andrew Witty, CEO

Key highlights

  • Q2 reported sales -2%
  • EPS before major restructuring* 25p
  • Underlying sales growth of 5%
  • Increased pipeline visibility and dividend of 16p, up 7%

 

2011 First Quarter - released on 27 April 2011

Key highlights

  • Reported sales -10%, underlying sales +4%
  • EPS before major restructuring 32.2p (+9%), dividend 16p (+7%)

 

2010 Fourth Quarter - released on 3 February 2011

"We have substantially re-engineered GSK’s business model over the last two and a half years, through major restructuring and a rigorous returns-based approach to capital allocation."


Andrew Witty, CEO

Key highlights

  • Long-term share buy-back programme initiated
  • 2010 dividend up 7% to 65p

 

2010 Third Quarter - released on 21 October 2010

Key highlights

  • Q3 EPS before major restructuring of 28.2p
  • Q3 dividend up 7% to 16p

 

2010 Second Quarter - released on 21 July 2010

"We are making good progress to build our group of healthcare businesses which offer sustainable growth and have complementary risk/value profiles. At the same time, we have also taken action to drive improved returns on invested capital in our core R&D operation."


Andrew Witty, CEO

Key highlights

  • Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge)
  • Q2 dividend increased 7% to 15p

 

2010 First Quarter - released on 28 April 2010

Key highlights

  • Q1 sales £7.4bn up 13% CER
  • Underlying sales (excluding pandemic products) up 4% CER